SLC5A2 and diabetic kidney disease: Current treatments for diabetic nephropathy, such as sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and renin–angiotensin–aldosterone system (RAAS) inhibitors, delay disease progression, and suppress protein O‐GlcNAcylation.